Atrasentan (Vanrafia) was approved in 2025 for the treatment of IgAN in people who are at risk of their disease getting worse quickly. It belongs to a class of medicines called endothelin receptor ...

The U.S. FDA approved 20 drugs for market in April, slightly down from 22 in March, 16 in February and 12 in January. This ...

Novartis’ $1.7 billion Regulus Therapeutics buyout last month came after a hard-fought battle in which the Swiss pharma and ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

Rouzbeh Haghighat was serving on the board of Chinook Therapeutics at the time of the Novartis acquisition and, according to the DOJ’s allegations, used confidential information to conduct insider ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Vanrafia®, also from Novartis, has just received its first approval and is poised to further expand the treatment armamentarium. Together, these products—alongside pipeline agents targeting the ...